

METHODOLOGY

1 application/day for **3 months**
In **monotherapy**
In **association** or as a **relay** to treatment and/or **emerging therapies**

13
countries



- **Europe** : Greece, Spain, Italy, Germany, French overseas
- **Middle East** : Saudi Arabia, United Arab Emirates
- **Africa** : Morocco, Tunisia, Senegal, Ivory Coast
- **East Asia** : South Korea
- **South America** : Venezuela

180 DERMATOLOGISTS

1676 adult patients with **CHRONIC HAIR LOSS**
All ethnicities (hair & phototype)



PRESCRIPTION SCHEME




POPULATION

18-93 years
mean: 40
66% ♀ | **34%** ♂



All phototypes

CHRONIC HAIR LOSS



• International, post-marketing study on ANAPHASE NEOPTIDE serum, applied once daily on 1676 subjects with chronic hair loss
• n=number of subjects

(1) Oral and topical
(2) Pooled finasteride & dutasteride
(3) Senescent alopecia affects people aged 50 years or older with no family history or evidence of pattern balding.

* Stem-cell therapy, low level light therapy, micro needling and other emerging therapies.

DERMATOLOGISTS CLINICAL EVALUATION



GREATER EFFECTIVENESS

WITH ANAPHASE NEOPTIDE SERUM IN COMBINATION WITH EMERGING THERAPY (PRP, mesotherapy...)

95%
GOOD TO VERY GOOD TOLERANCE

ANAPHASE NEOPTIDE serum, when combined with topical minoxidil and emerging therapies like PRP and mesotherapy, offers an effective and well-tolerated solution for androgenetic alopecia and chronic telogen effluvium.

Notably, ANAPHASE NEOPTIDE serum effectiveness is enhanced when combined with **EMERGING THERAPIES**.

•Hair density was assessed using an NRS scale from 0 (very slight) to 10 (very high). The reported number indicates the percentage change from baseline.
 •International, post-marketing study on Anaphase Neoptide serum, applied once daily on 1676 subjects with chronic hair loss.
 •n=number of subjects // *: p<0,05 **Emerging therapies: Platelet-Rich Plasma, Mesotherapy, Other emerging therapy...
 (1) Results significantly superior to monotherapy p<0.05